Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TAF1 | P21675 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | KDM6A | O15550 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743181 | 0.78 | LMNA (0.61) | MAPTCYP2C9LMNAKDM4EALDH1A1 | |
| SCHEMBL25331540 | 0.77 | LMNA (0.59) | MAPTCYP2C9LMNAKDM4EALDH1A1 | |
| SCHEMBL16019365 | 0.77 | PGR (0.37) | MAPTCYP2C9LMNAKDM4EALDH1A1 | |
| SCHEMBL171187 | 0.75 | GRM2 (0.54) | LMNAKDM4EALDH1A1SMN1; SMN2MEN1 | |
| Ricinine SCHEMBL257955 | 0.74 | MAPT (1.00) | MAPTCYP2C9LMNAKDM4EALDH1A1 | |
| SCHEMBL26596828 | 0.74 | LMNA (0.56) | MAPTCYP2C9LMNAKDM4EALDH1A1 | |
| SCHEMBL4131086 | 0.74 | GRM2 (0.42) | KDM4EALDH1A1GRM2MAPK1 | |
| SCHEMBL169741 | 0.74 | GRM2 (0.64) | GRM2 | |
| SCHEMBL11212583 | 0.72 | KDM4E (0.45) | MAPTCYP2C9LMNAKDM4EALDH1A1 | |
| SCHEMBL16793353 | 0.72 | ALDH1A1 (1.00) | MAPTCYP2C9LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| WO-2024116528-A1 | FLUORINE-CONTAINING PYRIDONE COMPOUND AND METHOD FOR PRODUCING SAME | ユニマテック株式会社 | 2024-06-06 | — | — | WO | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220098207-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | disclosed |
| WO-2022067082-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, LLC (US) | 2022-03-31 | — | — | WO | disclosed |
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| EP-2386861-A2 | Cross-ß structure binding compounds | Crossbeta Biosciences B.V. (NL) | 2011-11-16 | — | — | EP | disclosed |
| CN-101835756-A | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive MGLUR2 receptor modulators | JANSSEN PHARMACEUTICA NV | 2010-09-15 | — | — | CN | disclosed |
| CN-101679349-A | 3-cyano-4- (4-phenyl-piperidin-1-yl) -pyridin-2-one derivatives | JANSSEN PHARMACEUTICA NV | 2010-03-24 | — | — | CN | disclosed |
| US-20100015126-A1 | Methods of Binding of Cross-Beta Structures By Chaperones | CROSSBETA BIOSCIENCES B.V. (NL) | 2010-01-21 | — | — | US | disclosed |
| US-20100015126-A1 | Methods of Binding of Cross-Beta Structures By Chaperones | CROSSBETA BIOSCIENCES B.V. (NL) | 2010-01-21 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| WO-2007108675-A1 | METHODS OF BINDING OF CROSS-BETA STRUCTURES BY CHAPERONES | CROSSBETA BIOSCIENCES B.V. (NL) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007008072-A2 | CROSS-ß STRUCTURE BINDING COMPOUNDS | CROSSBETA BIOSCIENCES B.V. (NL) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | MAPT 4344/4885CYP2C9 1610/4885LMNA 1618/4885 |
| US-20100015126-A1 | Methods of Binding of Cross-Beta Structures By Chaperones | HSP90B1, HSPB1, HSPA5 | MAPT 1929/4885CYP2C9 4409/4885LMNA 2072/4885 |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | MAPT 2206/4885CYP2C9 4497/4885LMNA 1451/4885 |
| US-20220098207-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CAMK2B, CAMK2A, CAMK2G | MAPT 2841/4885CYP2C9 1145/4885LMNA 3628/4885 |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | PRDX6, PRDX1, CBR3 | MAPT 4783/4885CYP2C9 88/4885LMNA 4229/4885 |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CAMK2B, RYR2, CAMK2A | MAPT 2976/4885CYP2C9 1491/4885LMNA 3703/4885 |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CAMK2B, RYR2, CAMK2A | MAPT 2976/4885CYP2C9 1491/4885LMNA 3703/4885 |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | MAPT 4141/4885CYP2C9 2562/4885LMNA 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.